Ultrahigh-dose methylcobalamin in early ALS
A 16-week randomized clinical trial in Japanese patients with early-stage ALS and moderate progression reported slower functional decline with ultrahigh-dose methylcobalamin than with placebo.
This clinical regimen does not establish equivalence with the model inputs shown on this page.
Oki et al., 2022 →